Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis
J. Clin. Invest. Tomohiro Watanabe, et al. 118:545 doi:10.1172/JCI33145 [Go to this article.]

Figure 5
DSS colitis in MDP-treated NOD2-deficient mice reconstituted with intact or frameshift NOD2. NOD2-deficient (NOD2^–/–) mice were treated with drinking water containing 5.5% DSS for 6 days (days 0–5). At an early phase of colitis induction (days 0, 1, 2), mice were administered MDP and HVJ-encapsulated plasmid (see Methods). (A) Changes in body weight in MDP-administered NOD2-deficient mice reconstituted with intact NOD2, frameshift NOD2, or control empty vector. Weights of MDP-administered NOD2-deficient mice given DSS are shown as a control. **P < 0.01, time point values of intact-NOD2–reconstituted mice compared with control empty vector–reconstituted mice. (B) H&E-stained colonic tissue of the mice harvested on day 7. Original magnification, ×50.